First report of antioxidant 1H-benzochromenone from muricid gastropod Chicoreus ramosus as dual inhibitors of pro-inflammatory 5-lipoxygenase and carbolytic enzymes.

Chromene derivatives with manifold structural framework and pharmacological properties were ubiquitous in the mollusks of marine origin. A previously undescribed 1H-benzochromenone was isolated through bioassay-guided chromatographic purification of the organic extract of the marine gastropod mollusk Chicoreus ramosus. The compound was characterised as 6-(2',2'-dimethyl)-3'-en-1'-yl-1'-oxy)-3-hydroxy-1H-benzo[c]chromene-2(10aH)-one based on integrated spectroscopic analysis. The antioxidant studies by employing the stable free radicals reported that the antioxidant activity (IC₅₀ 1.4-1.6 mM) was comparable to α-tocopherol (IC₅₀ 1.4-1.7 mM). The attenuating potential of the studied compound against pro-inflammatory 5-lipoxygenase (IC₅₀ 2.12 mM) was significantly greater than that exhibited by anti-inflammatory drug ibuprofen (IC₅₀ 4.4 mM), whereas its inhibitory properties against carbolytic α-amylase (IC₅₀ ∼0.72 mM) was comparable with that displayed by acarbose (IC₅₀ 0.43 mM). The present study recognised the potential of 1H-benzochromenone derivative isolated from C. ramosus as important pharmaceutical lead with anti-diabetic and anti-inflammatory potentials to reduce the risk of hyperglycaemia and inflammatory pathologies.